Gentian Diagnostics AS announces its results for the first quarter of 2021. The highlights include:
Record sales revenue of MNOK 19.6 in 1Q21, a 33 % organic growth. Reported growth of 24 % on a currency neutral basis as 1Q20 includes revenues from the subsidiary PreTect AS, which was divested in 2H20.
Growth of 60 % versus Q1 last year in fCAL® turbo sales.
Increased commercial momentum for GCAL®, displaying early signs of the next revenue level, with new routine users in several European countries and new distribution contracts.
Expanded NT-proBNP development scope in order to enable industry standardisation, expected to positively impact adoption rates. New launch date set to 1Q22.
Decision to apply for a listing of the shares at Oslo Børs Main market. It is envisaged that a transfer of the listing from Euronext Growth to the main market will take place towards the latter part of 1H21.
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.com.